Targeted delivery of radiolabeled imaging and therapeutic agents: Bifunctional radiopharmaceuticals

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 16, Issue 2, 1999, Pages 209-244

  Saji, Hideo ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Bifunctional radiopharmaceutical; Diagnosis; Metallic radionuclide; Targeting; Therapy

Indexed keywords

CARBON 11; COPPER 67; FLUORINE 18; GADOTERIC ACID; GALLIUM 67; INDIUM 111; IODINE 123; IODINE 131; NITROGEN 13; OXYGEN 15; PENTETATE INDIUM IN 111; PENTETIC ACID DERIVATIVE; QUINUCLIDINYL BENZILATE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; SAMARIUM 153; STRONTIUM 89; TECHNETIUM 99M; THALLIUM 201; YTTRIUM 90; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M;

DIAGNOSTIC VALUE; DRUG DELIVERY SYSTEM; HUMAN; ISOTOPE LABELING; NONHUMAN; NUCLEAR MEDICINE; REVIEW;

EID: 0032959666     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (158)

1. Barrio, J. R., Biochemical principles in radiopharmaceutical design and utilization, in Positron Emission Tomography and Autoradiography, Phelps, M. E., Mazziotta, J. C., and Schiebert, H. R., Eds., New York: Raven Press, 1986; 451.
2. Hung, S. C. and Phelps, M. E., Principles of tracer kinetic modeling, in Positron Emission Tomography and Autoradiography, Phelps, M. E., Mazziotta, J. C., and Schlebert, H. R., Eds., New York: Raven Press, 1986; 287.
3. Chilton, H. M. and Witcofski, R. L., Radiopharmaceuticals for imaging tumors and inflammatory processes: Gallium, antibodies, and leukocytes, in Pharmaceuticals in Medical Imaging, Swanson, D. P., Chilton, H. M., and Thrall, J. H., Eds., New York: MacMillan Publishing, 1990; 564.
4. Balant, L. P., Roseboom, H., and Gundert-Renny, U. M., Pharmacokinetic criteria for drug research and development, in Advances in Drug Research, Testa, B., Ed., London: Academic Press, 1990; 1.
5. Phelps, M. E., PET: A biological imaging technique, Neurochem. Res., 16, 929, 1991.
6. Stocklin, G., Tracers for metabolic imaging of brain and heart: Radiochemistry and radiopharmacology, Eur. J. Nucl. Med., 19, 527, 1992.
7. Schochau, K., Technetium radiopharmaceuticals: Fundamentals, synthesis, structure, and development, Angew. Chem. Int. Ed. Engl., 33, 22258, 1994.
8. Horiuchi, K. S. and Yokoyama, A., Radioactive metal complexes used for tumor diagnosis, in Handbook of Metal-Ligand Interactions in Biological Fluids, Berthon, G., Ed., New York: Marcel Dekker, 1995; 1052.
9. Verbruggen, A. M., Bifunctional chelators for technetium-99m, in Current Directions in Radiopharmaceutical Research and Development, Mather, S. J., Ed., Dordrecht; Kluwer Academic Publishers, 1996; 31.
10. Dilworth, J. R. and Parrott, S. J., Radiopharmaceutically relevant chemistry of technetium and rhenium, in Current Directions in Radiopharmaceutical Research and Development, Mather, S. J., Ed., Dordrecht: Kluwer Academic Publishers, 1996; 1.
11. Eckelman, W. C., Paik, C. H., and Reba, R. C., Radiolabeling of antibodies, Cancer Res., 40, 3036, 1980.
12. Yokoyama, A., Recent progress in the development of bifunctional radiopharmaceuticals, in Radiopharmaceuticals and Labeled Compounds, Vienna: IAEA, 1985; 251.
13. Sunberg, M. W., Meares, C. F., Goodwin, D. A., and Diamanti, C. I., Chelating agents for the binding of metal ions to macromoleculers, Nature, 250, 587, 1974.
14. Meares, C. F., Goodwin, D. A., Leung, C. S.-H., Girgis, A. Y., Silvester, D. J., Nunn, A. D., and Lavender, P. L., Covalent attachment of metal chelates to proteins: The stability in vivo and in vitro of the conjugate of albumin with a chelate of 111-indium, Proc. Natl. Acad. Sci. USA, 73, 3803, 1976.
15. 99mTc-labeling of antibodies, Nucl. Med., 26, 7, 1987.
16. Hasen, H. J., Jones, A. L., Grebenau, R., Kunz, A., and Goldenberg, D. M., Labeling of anti-tumor antibodies and antibody fragments with Tc-99m, Cancer Treatment Res., 51, 233, 1990.
17. Koppel, G. A., Recent advances with monoclonal antibody drug targeting for the treatment of human cancer, Bioconj. Chem., 1, 13, 1990.
18. Demon-Moingeon, L. I., Mahmood, A., Davison, A., and Jones, A. G., Strategies for labeling monoclonal antibodies and antibody-like molecules with technetium-99m, J. Nucl. Med., 35, 47, 1991.
19. Griffiths, G. L., Goldenberg, D. M., Jones, A. L., and Hansen, A. J., Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium, Bioconj. Chem., 3, 91, 1992.
20. Brinkley, M., A brief survey of methods for preparing protein conjugates with dyes, haptens, and cross-linking reagents, Bioconj. Chem., 3, 2, 1992.
21. Jurisson, S., Berning, D., Jia, W., and Ma, D., Coordination compounds in nuclear medicine, Chem. Rev., 93, 1137, 1993.
22. Fischman, A. J., Pike, M. C., Kroon, D., Fucello, A. J., Rexinger, D., tenKate, C., Wilkinson, R., Rubin, R. H., and Strauss, H. W., Imaging focal sites of bacterial infection in rats with indium-111-labeled chemotactic peptide analogs, J. Nucl. Med., 32, 483, 1991.
23. Fischman, A. J., Badich, J. W., and Strauss, H. W., A ticket to ride: Peptide radiopharmaceuticals, J. Nucl. Med., 34, 2253, 1993.
24. Hom, R. K. and Katzenellenbogen, J. A., Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: Recent developments and encouraging results, Nucl. Med. Biol., 24, 485, 1997.
25. Britton, K. E., Mather, S. J., and Granowska, M., Radiolabelled monoclonal antibodies in oncology, III. Radioimmunotherapy, Nucl. Med. Comm., 12, 333, 1991.
26. Jon, E., Thakur, M. L., DeFulvio, J., McDevitt, M. R., and Damjanov, I., Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Preparation and evaluation, J. Nucl. Med., 34, 260, 1993.
27. van Dongen, G. A. M. S., Brakenhoff, R. H., De bree, R., Gerretsen, M., Quak, J. J., and Snow, G. B., Progress in radioimmunotherapy of head and neck cancer, Oncol. Reports, 1, 259, 1994.
28. Larson, S. M., Digvi, C. R., and Scott, A., Current status of radioimmunotherapy, Nucl. Med. Biol., 21, 785, 1994.
29. Wilder, R. B., DeNardo, G. L., and DeNardo, S. J., Radioimmunotherapy: Recent results and future directions, J. Clin. Oncol., 14, 1383, 1996.
30. Srivastava, S. C., Therapeutic radionuclides: Making the right choice, in Current Directions in Radiopharmaceutical Research and Development, Mather, S. J., Ed., Dordrecht: Kluwer Academic Publishers, 1996; 63.
31. Hoefnagel, C. A., Radionuclide cancer therapy, Ann. Nucl. Med., 12, 61, 1998.
32. Chatal, J. F. and Mahe, M., Therapeutic use of radiolabelled antibodies, in Nuclear Medicine in Clinical Diagnosis and Treatment, 2nd ed., Murray, I. P. C. and Ell, P. J., Eds., Edinburgh: Churchill Livingstone, 1998; 1.
33. 15O. I. Theory and error analysis, J. Nucl. Med., 24, 782, 1983.
34. 15O-water, J. Cereb. Blood Flow Metabol., 3, 141, 1983.
35. Ter-pogossian, M. M. and Herscovitch, P., Radioactive oxygen-15 in the study of cerebral blood flow, blood volume and oxygen metabolism, Sem. Nucl. Med., 15, 377, 1985.
36. Dischino, D. D., Development of positron emitting brain perfusion agents, in Radiopharmaceuticals: Chemistry and Pharmacology, Nunn, A. D., Ed., New York: Marcel Dekker, 1992; 1.
37. Fukuyama, H., Ogawa, M., Yamauchi, H., Yamaguchi, S., Kimura, J., Yonekura, Y., and Konishi, J., Altered cerebral energy metabolism in Alzheimer's disease: A PET study, J. Nucl. Med., 35, 1, 1994.
38. Honda, M., Nagamine, T., Fukuyama, H., Yonekura, Y., Kimura, J., and Shibasaki, H., Movement-related cortical potentials and regional cerebral blood flow change in patients with stroke after motor recovery, J. Neurol. Sci., 146, 117, 1997.
39. Kung, H. F., Ohmomo, Y., and Kung, M.-P., Current and future radiopharmaceuticals for brain imaging with single photon emission computed tomography, Sem. Nucl. Med., 20, 290, 1990.
40. Nowotnik, D. P., Technetium-based brain perfusion agents, in Radiopharmaceuticals: Chemistry and Pharmacology, Nunn, A. D., Ed., New York: Marcel Dekker, 1992; 37.
41. 99mTc-KTS, Int. J. Nucl. Med. Biol., 12, 431, 1986.
42. Holman, B. L., Hellman, R. S., Goldsmith, S. J., Mena, I. G., Leveille, J., Gherrardi, P. G., Moretti, J. L., Bischof-Delaloye, A., Hill, T. C., and Rigo, P. M., Biodistribution, dosimetry, and clinical evaluation of technetium-99m ethyl cysteinate dimer in normal subjects and in patients with chronic cerebral infarction, J. Nucl. Med., 30, 1018, 1989.
43. Walovitch, R. C., Hill, T. C., Garrity, S. T., Cheesman, E. H., Burgess, B. A., O'Leary, D. H., Watson, A. D., Ganey, M. V., Morgan, R. A., and Williams, S. J., Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, Part I: Pharmacology of technetium-99m ECD in nonhuman primates, J. Nucl. Med., 30, 1892, 1989.
44. Leveille, J., Demonceau, G., De Roo, M., Rigo, P., Tailefer, R., Morgan, R. A., Kupranick, D., and Walovitch, R. C., Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, Part 2. Biodistribution and brain imaging in humans, J. Nucl. Med., 30, 1902, 1989.
45. Kung, H. F., Radiopharmaceuticals for CNS receptor imaging with SPECT, Nucl. Med. Biol., 17, 85, 1990.
46. Eckelman, W. C., The development of single-photon emitting receptor-binding radiotracers, in Radiopharmaceuticals: Chemistry and Pharmacology, Nunn, A. D., Ed., New York: Marcel Dekker, 1992; 167.
47. Langstrom, B. and Hartvig, P., Positron emitting receptor tracers in studies of neurotransmission and receptor binding, in Radiopharmaceuticals: Chemistry and Pharmacology, Nunn, A. D., Ed., New York: Marcel Dekker, 1992; 221.
48. Kung, H. F., The development of radiopharmaceuticals for imaging CNS receptors, in Current Directions in Radiopharmaceutical Research and Development, Mather, S. J., Ed., Dordrecht: Kluwer Academic Publishers, 1996; 99.
49. Kung, H. F., Kim, H.-J., Kung, M.-P., Meegalla, S. K., Plossl, K., and Lee, H.-K., Imaging of dopamine transporters in humans with technetium-99m TRODAT-1, Eur. J. Nucl. Med., 23, 1527, 1996.
50. Meltzer, P. C., Blundell, P., Jones, A. G., Mahmood, A., Garada, B., Zimmerman, R. E., Davison, A., Holman, L., and Madras, B. K., A technetium-99m SPECT imaging agent which targets dopamine transporter in primate brain, J. Med. Chem., 40, 1835, 1997.
51. Welch, M. J., Downer, J. B., and Katzenellenbogen, J. A., Steroid hormone receptors as targets for diagnostic imaging, in Current Directions in Radiopharmaceutical Research and Development, Mather, S. J., Ed., Dordrecht: Kluwer Academic Publishers, 1996; 137.
52. Hancock, R. D., Computer modelling of metal-based radiopharmaceuticals, in Current Directions in Radiopharmaceutical Research and Development, Mather, S. J., Ed., Dordrecht: Kluwer Academic Publishers, 1996; 201.
53. Jurisson, S. S., Pirro, J., DiRocco, R. J., Rosenspire, K. C., Jagoda, E., Nanjappan, P., Eckelaman, W. C., Nowotnik, D. P., and Nunn, A. D., Boronic acid adducts of technetium dioxime (BATO) complexes derived from quinuclidine benzilate (QNB) boronic acid stereoisomers: Syntheses and studies of their binding to the muscarinic acethylcholine receptor, Nucl. Med. Biol., 22, 269, 1995.
54. 99m/99Tc-DADT-benzovesamicol: A potential marker for cholinergic neurons, Nucl. Med. Biol., 21, 197, 1994.
55. DiZio, J. P, Fiaschi, R., Davison, A., Jones, A. G., and Katzenellenbogen, J. A., Progestin-rhenium complexes: Metal-labeled steroids with high receptor binding affinity, potential receptor-directed agents for diagnostic imaging or therapy, Bioconj. Chem., 2, 353, 1991.
56. DiZio, J. P, Anderson, C. J., Davison, A., Ehrhardt, G. J., Carlson, K. E., Welch, M. J., and Katzenellenbogen J. A., Technetium- and rhenium-labeled progestins: Synthesis, receptor binding and in vivo biodistribution of an 11β-substituted progestin labeled with technetium-99 and rhenium-186, J. Nucl Med., 33, 558, 1992.
57. O'Neil, J. P., Wilson, S. R., and Katzenellenbogen, J. A., Preparation and structural characterization of monoamine-monoamide bis(thiol) oxo complexes of technetium(V) and rhenium(V), Inorg. Chem., 33, 319, 1994.
58. 2-metal conjugate, Bioconj. Chem., 5, 182, 1994.
59. Lever, S. Z., Baidoo, K. E., Mahmood, A. M., Matsumura, K., Schefel, U., and Wagner, Jr., H. N., Novel technetium ligands with affinity for the muscarinic cholinergic receptor, Nucl. Med. Biol., 21, 157, 1994.
60. Chi, D. Y., O'Neil, J. P., Anderson, C. J., Welch, M. J., and Katzenellenbogen, J. A., Homodimeric and heterodimeric bis(amino thiol)oxometal complexes with rhenium(V) and technetium(V). Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones, J. Med. Chem., 37, 928, 1994.
61. Hom, P. K., Chi, D. Y., and Katzenellenbogen, J. A., Heterodimeric bis(amino thiol) complexes of oxorhenium(V) that mimic the structure of steroid hormones: Synthesis and stereochemical issues, J. Org. Chem., 61, 2624, 1996.
62. Krejcarek, G. E. and Tucker, K. L., Covalent attachment of chelating groups to macromolecules, Bioc. Biop. Res. Comm., 77, 581, 1977.
63. Hnatowich, D. J., Layne, W. W., Childs, R. L., Lanteigne, D., Davis, M. A., and Griffin, T. W., Radioactive labeling of antibody: A simple and efficient method, Science, 220, 613, 1983.
64. Paik, C. H., Murphy, P. R., Eckelman, W. C., Volkert, W. A., and Reba, R. C., Optimization of the DTPA mixed-anhydride reaction with antibodies at low concentration, J. Nucl. Med., 24, 932, 1983.
65. Paik, C. H., Ebbert, M. A., Murphy, P. R., Lassman, C. R., Reba, R. C., Eckelman, W. C., Pak, K. Y., Powe, J., Steplewski, Z., and Koprowski, H., Factors influencing DTPA conjugation with antibodies by cyclic DTPA anhydride, J. Nucl. Med., 24, 1158, 1983.
66. Westerberg, D. A., Carney, P. L., Rogers, P. E., Kline, A. J., and Johnson, D. K., Synthesis of novel bifunctional chelators and their use in preparing monoclonal antibody conjugates for tumor targeting, J. Med. Chem., 32, 236, 1989.
67. 111In-labeled monoclonal antibodies in normal animals and nude mouse-human tumor models, Cancer Res., 43, 5347, 1983.
68. Khaw, B. A., Strauss, H. W., Cahill, S. J., Soule, H. R., Edgington, T., and Cooney, J., Sequential imaging of indium-111-labeled monoclonal antibody in human mammary tumors hosted in nude mice, J. Nucl. Med., 25, 592, 1984.
69. Khaw, B. A., Cooney, J., Edgington, T., and Strauss, H. W., Differences in experimental tumor localization of dual-labeled monoclonal antibody, J. Nucl. Med., 27, 1293, 1986.
70. Brown, B. A., Comeau, R. D., Jones, P. L., Liberatore, F. A., Neacy, W. P., Sands, H., and Gallagher, M., Pharmacokinetics of the monoclonal antibody B72.3 and its fragments labeled with either I-125 or In-111, Cancer Res., 47, 1149, 1987.
71. Larson, S. M. and Carrasquillo, J. A., Advantages of radioiodine over radioindium labeled monoclonal antibodies for imaging solid tumor, Nucl. Med. Biol., 15, 231, 1988.
72. Koizumi, M., Endo, K., Watanabe, Y., Saga, T., Sakahara, H., Konishi, J., Yamamuro, T., and Toyama, S., Pharmacokinetics of internally labeled monoclonal antibodies as a gold standard: Comparison of biodistribution of Se-75-, In-111-, and I-125-labeled monoclonal antibodies in osteogenic sarcoma xenografts in nude mice, Cancer Res., 49, 1752, 1989.
73. Paik, C. H., Sood, V. K., Le, N., Cioloca, L., Carrasquillo, J. A., Reynolds, J. C., Neumann, R. D., and Reba, R. C., Radiolabeled products in rat liver and serum after administration of antibody-amide-DTPA indium-111, Nucl. Med. Biol., 19, 517, 1992.
74. Motta-Hennessy, C., Sharkey, R. M., and Goldenberg, D. M., Metabolism of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse, J. Nucl. Med., 31, 1510, 1990.
75. 111In-labeled antibodies, Nucl. Med. Biol., 16, 839, 1989.
76. Hnatowich, D. J., Childs, R. L., Lanteigne, D., and Najafi, A. J., The preparation of DTPA coupled antibodies radiolabeled with metallic radionuclides: An improved method, J. Immunol. M., 65, 145, 1983.
77. 1-octreotide synthesis, Bioconj. Chem., 8, 442, 1997.
78. Meares, C. F., McCall, M. J., Reardan, D. T., Goodwin, D. A., Diamanti, C. I., and McTigue, M., Conjugation of antibodies with bifunctional chelating agents: Isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition to metal ions, Anal. Biochem., 142, 68, 1984.
79. Deshpande, S. V., Subramanian, R., McCall, M. J., DeNardo, S. J., DeNardo, G. L., and Meares, C. F., Metabolism of indium chelates attached to monoclonal antibody: Minimal transchelation of indium from benzyl-EDTA chelate in vivo, J. Nucl. Med., 31, 218, 1990.
80. Arano, Y., Uezono, T., Akizawa, H., Ono, M., Wakisaka, K., Kakayama, M., Sakahara, H., Konishi, J., and Yokoyama, A., Reassessment of diethylenetriaminepentaacetic acid (DTPA) as a chelating agent for indium-111 labeling a newly synthesized monoreactive DTPA derivative, J. Med. Chem., 39, 3451, 1996.
81. Yokoyama, K., Carrasquillo, J. A., Chang, A. E., Colcher, D., Roselli, M., Sugarbaker, P., Sindelar, W., Reynolds, J. C., Perentesis, P., Gansow, O. A., Francis B., Adams, R., Finn, R., Schlom, J., and Larson, S. M., Differences in biodistribution of indium-111-and iodine-131-labeled b72. 3 monoclonal antibodies in patients with colorectal cancer, J. Nucl. Med., 30, 320, 1989.
82. Duncan, J. R. and Welch, M. J., Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins, J. Nucl. Med., 34, 1728, 1993.
83. Franano, F. N., Edwards, W. B., Welch, M. J., and Duncan, J. R., Metabolism of receptor targeted In-111-DTPA-glycoproteins: Identification of In-111-DTPA-epsilon-lysine as the primary metabolic and excretory product, Nucl. Med. Biol., 21, 1023, 1994.
84. Boyle, C. C., Paine, A. J., and Mather, S. J., The mechanism of hepatic uptake of a radio-4 labeled monoclonal antibody, Int. J. Cancer, 50, 912, 1992.
85. Arano, Y., Mukai, T., Uezono, T., Wakisaka, K., Motonari, H., Akizawa, H., Taoka, Y., and Yokoyama, A., A biological method to evaluate bifunctional chelating agents to label antibodies with metallic radionuclides, J. Nucl. Med., 35, 890, 1994.
86. Arano, Y., Antibody-associated chelates for targeted imaging, in Handbook of Targeted Delivery of Imaging Agents, Torchilin, V. P., Ed., Boca Raton: CRC Press, 1995; 103.
87. Rogers, B. E., Franano, F. N., Duncan, J. R., Edwards, W. B., Anderson, C. J., Connett, J. M., and Welch, M. J., Identification of metabolites of 111-In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo, Cancer Res., 55 (Suppl.), S5714, 1995.
88. Ashwell, G. and Harford, J., Carbohydrate-specific receptors of the liver, Ann. Rev. Bioch., 51, 531, 1982.
89. 111In chelate conjugated anti-idiotype monoclonal antibody for radioimmunodetection of lymphoma in mice, Eur. J. Nucl. Med., 12, 455, 1986.
90. Deshpande, S. V., DeNardo, S. J., Meares, C. F., McCall, M. J., Adams, G. P., and DeNardo, G. L., Effect of different linkages between chelates and monoclonal antibodies on levels of radioactivity in the liver, Nucl. Med. Biol., 16, 587, 1989.
91. Paik, C. H., Quadri, S. M., and Reba, R. C., Interposition of different chemical linkages between antibody and 111-In-DTPA to accelerate clearance from non-target organs and blood, Nucl. Med. Biol., 16, 475, 1989.
92. Paik, C. H., Yokoyama, K., Reymonds, J. C., Quadri, S. M., Min, C. Y., Shin, S. Y., Maloney, P. J., Larson, S. M., and Reba, R. C., Reduction of background activities by introduction of a diester linkage between antibody and a chelate in radioimmunodetection of tumor, J. Nucl. Med., 30, 1693, 1989.
93. Arano, Y., Wakisaka, K., Ohmomo, Y., Uezono, T., Mulai, T., Motonari, H., Shiono, H., Sakahara, H., Konishi, J., Tanaka, C., and Yokoyama, A., Maleimidoethl 3-(tri-n-butylstannyl)hippurate: A useful radioiodination reagent for protein radiopharmaceuticals to enhance target selective radioactivity localization, J. Med. Chem., 37, 2609, 1994.
94. Arano, Y., Wakisaka, K., Ohmono, Y., Uezono, T., Akizawa, H., Nakayama, M., Sakahara, H., Tanaka, T., Konishi, J., and Yokoyama, A., Assessment of radiochemical design of antibodies using an ester bond as the metabolizable linkage: Evaluation of maleimidoethyl 3-(tri-n-butylstannyl)hippurate as a radioiodination reagent of antibodies for diagnostic and therapeutic applications, Bioconj. Chem., 7, 628, 1996.
95. Wakisaka, K., Arano, Y., Uezono, T., Akizawa, H., Ono, M., Kawai, K., Ohmomo, Y., Nakayama, M., and Saji, H., A novel radioiodination reagent for protein radiopharmaceuticals with L-lysine as a plasima-stable metabolizable linkage to liberate m-iodohippuric acid after lysosomal proteolysis, J. Med. Chem., 40, 2643, 1997.
96. Arano, Y., Wakisaka, K., Akizawa, H., Ono, M., Kawai, K., Nakayama, M., Sakahara, H., Konishi, J., and Saji, H., Assessment of the radiochemical design of antibodies with a metabolizable linkage for target-selective radioactivity delivery, Bioconj. Chem., 9, 497, 1998.
97. Goldstein, A., Arnow, L., and Kalman, S. M., Chemical pathways of drug metabolism, in Principles of Drug Action, 2nd ed., New York: Wiley, 1974, 242.
98. Zalutsky, M. R. and Narula, A. S. A., A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine, Appl. Rad. Is., 38, 1051, 1987.
99. Garg, P. K., Slade, S. K., Harrison, C. L., and Zalutsky, M. R., Labeling proteins using aryl iodide acylation agents: Influence of meta vs. para substitution on in vivo stability, Nucl. Med. Biol., 16, 669, 1989.
100. Stewart, L. M. D., Genetic engineering of monoclonal antibodies, in Current Directions in Radiopharmaceutical Research and Development, Mather, S. J., Ed., Dordrecht: Kluwer Academic Publishers, 1996; 89.
101. Yokota, T., Milenic, D. E., Whitlow, M., Wood, J. F., Hubert, S. L., and Schlom, J., Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms, Cancer Res., 53, 3776, 1993.
102. Webber, K. O., Kreitman, R. J., and Pastan, I., Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors, Cancer Res., 55, 318, 1995.
103. King, D. J., Turner, A., Fransworth, A. P. H., Improvement tumor targeting with chemically cross-linked recombinant antibody fragments, Cancer Res., 54, 6176, 1994.
104. Zhu, H., Baxter, L. T., and Jain, R. K., Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies, J. Nucl. Med., 38, 731, 1997.
105. Christensen E. J. and Maunsbach, A. B., Intralysosomal digestion of lysozyme in renal proximal tubule cells, Kidney Int., 6, 396, 1974.
106. Maack, T., Johnson, V., Kau, S. T., Figueiredo, J., and Sigulem, D., Renal filtration, transport and metabolism of low molecular weight proteins: A review, Kidney Int., 16, 251, 1979.
107. Carone, F. A. and Peterson, D. R., Hydrolysis and transport of small peptides by the proximal tubule, J. Physiol., 238, F151, 1980.
108. Carone, F. A., Peterson, D. R., and Flouret, G., Renal tubular processing of small peptide hormones, J. Lab. Clin. Med., 100, 1, 1980.
109. Silberbagl, S., The renal handling of amino acids and oligopeptides, Phys. Rev., 68, 811, 1988.
110. Arano, Y., Wakisaka, K., Akizawa, H., Ono, M., Fujioka, Y., Uehara, T., Saga, H., Sakahara, H., Konishi, J., and Saji, H., A chemical strategy to reduce renal radioactivity levels of antibody fragments, in Synthesis and Applications of Isotopically Labelled Compounds, Heyes, J. R. and Melillo, D. G., Eds., Chichester: Wiley, 1998; 307.
111. Krenning, E. P., Bakker, W. H., Breeman, W. A. P., Koper, J. W., Kooij, P. P., Ausema, L., Lameris, J. S., Reubi, J. C., and Lamberts, S. W., Localization of endocrine-related tumors with radioiodinated analogue of somatostatin, Lancet, 1, 242, 1989.
112. Bakker, W. H., Krenning, E. P., Breeman, W. A., Koper, J. W., Kooji, P. P., Reubi, J.-C., Kliji, J. G., Visser T. J., Docter, R., and Lamberts, S. W., Receptor scintigraphy with a radioiodinated somatostatin analogue: Radiolabeling, purification, biologic activity, and in vivo application in animals, J. Nucl. Med., 31, 1501, 1990.
113. 1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation, Life Sci., 49, 1583, 1991.
114. 3]-octreotide: The Rotterdam experience with more than 1000 patients, Eur. J. Nucl. Med., 20, 716, 1993.
115. Knight, L. C., Radcliffe, R., Maurer, A. H., Rodwell, J. D., and Alvarez, V. L., Thrombus imaging technetium-99m synthetic peptides based upon the binding domain of a monoclonal antibody to activated platelets, J. Nucl. Med., 35, 282, 1994.
116. Virgolini, I., Raderer, M., Kurtaran, A., Angelberger, P., Banyai, S., Yang, Q., Li, S., Banyai, M., Pidlich, J., Niederle, B., Scheithauer, W., and Valent, P., Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors, N. Eng. J. Med., 331, 1116, 1994.
117. Virgolini, I., Kurtaran, A., Raderer, M., Leimer, M., Angelberger, P., Havlik, E., Li, S., Scheithauer, W., Niederle, B., Valent, P., and Eichler, H. G., Vasoactive intestinal peptide receptor scintigraphy, J. Nucl. Med., 36, 1732, 1995.
118. Lister-James, J., Knight, L. C., Mauere, A. H., Bush, L. R., Moyer, B. R., and Den, R. T., Thrombus imaging with a technetium-99m-labeled activated platelet receptor-binding peptide, J. Nucl. Med., 37, 775, 1996.
119. Reubi, J. C., Neuropeptide receptors in health and disease: The molecular basis for in vivo imaging, J. Nucl. Med., 36, 1825, 1995.
120. Reubi, J. C., Waser, B., Reubi, J. C., Waser, B., Sheppard, M., and Macaulay, V., Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: Relationship to EGF-receptors, Int. J. Cancer, 45, 269, 1990.
121. Reubi, J. C., Waser, B., Foekens, J. A., Klijn, J. G. M., Lamberts, S. W. J., and Laissue, J., Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: Relationship to EGF-receptors, Int. J. Cancer, 46, 416, 1990.
122. Duncan, J. R., Stephenson, M. T., Wu, H. P., and Anderson, C. J., Indium-111-diethylene triaminepentaacetic acid-octreotide is delivered in vivo to pancreatic tumor cell, renal and hepatocyte lysosomes, Cancer Res., 57, 659, 1997.
123. 1-octreotide, Bioconj. Chem., 9, 192, 1998.
124. Smith-Jones, P. M., Stolz, B., Albert, R., Knecht, H., and Bruns, C., Synthesis, biodistribution and renal handling of various chelate-somatostatine conjugates with metabolizable linking groups, Nucl. Med. Biol., 24, 761, 1997.
125. Mogensen, C. E. and Solling, K., Studies on renal tubular protein reabsorption: Partial and near complete inhibition by certain amino acids, Scand. J. Clin. Invest., 37, 477, 1977.
126. Behr, T. M., Sharkey, R. M., Juweid, M. E., Blumenthal, R. D., Dunn, R. M., Griffiths, G. L., Bair, H. J., Wolf, F. G., Becker, W. S., and Goldenberg, D. M., Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives, Cancer Res., 55, 3825, 1995.
127. Virgolini, I., Yang, Q., Li, S. R., Angelberger, P., Neuhold, N., Niederle, B., Scheithauer, W., and Valent, P., Cross-competition between vasoactive intestinal peptide (VIP) and somatostatin for binding to tumor cell receptors. Cancer Res., 54, 690, 1994.
128. Raderer, M., Becherer, A., Kutaran, A., Angelberger, P., Li, S., Leimer, M., Weinlaender, G., Kornek, G., Kletter, K., Scheithauer, W., and Virgolini, I., Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-11-CYT-103 immunoscintigraphy, J. Nucl. Med., 37, 1480, 1996.
129. 2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer, J. Nucl. Med., 38, 1221, 1997.
130. Lanteigne, D. and Hnatowich, D. J., The labeling of DTPA-coupled proteins with 99mTc, Int. J. Appl. Rad. Is., 35, 617, 1984.
131. Cholds, R. L. and Hnatowich, D. J., Optimum conditions for labeling of DTPA-coupled antibodies with technetium-99m, J. Nucl. Med., 26, 293, 1985.
132. 99mTc labeling of proteins: p-carboxyehtylphenylglyoxal-di-(N-methylthiosemicarbazone), Nucl. Med. Biol., 12, 425, 1986.
133. Arano, Y., Yokoyama, A., Furukawa, T., Horiuchi, K., Yahata, T., Saji, H., Sakahara, H., Nakashima, T., Koizumi, M., Endo, K., and Torizuka, K., Technetium-99m-labeled monoclonal antibody with preserved immunoreactivity and high in vivo stability, J. Nucl. Med., 28, 1027, 1987.
134. Fritzberg, A. R., Abrams, P. G., Beaumier, P. L., Kasina, S., Morgan, A. C., Rao, T. N., Reno, J. M., Sanderson, J. A., Srinivasan, A., and Wilbur, D. S., Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent. Proc. Natl. Acad. Sci. USA, 85, 4025, 1988.
135. 186Re-labeling of monoclonal antibodies, Cancer Res., 54, 769, 1994.
136. Lever, S. Z., Baidoo, K. E., Kramer, A. V., and Burns, H. D., Synthesis of novel bifunctional chelate designed for labeling proteins with technetium-99m, Tetrahedr. Lett., 29, 3219, 1988.
137. 99mTc labeling of proteins: Initial evaluation of a novel diaminedithiol bifunctional chelating agent, Cancer Res., 50 (Suppl.), S799, 1990.
138. Badioo, K. E. and Lever, S. Z., Synthesis and a diaminedithiol bifunctional chelating agent for incorporation of technetium-99m into biomolecules, Bioconj. Chem., 1, 132, 1990.
139. Eisenhut, M., Lehmann, W. D., Becker, W., Behr, T., Elser, H., Strittmatter, W., Steinstrasser, A., Baum, R. P., Valerius, T., Repp, R., and Deo., Y., Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: Conjugation chemistry, immunoreactivity and kit formation, J. Nucl. Med., 37, 362, 1996.
140. 99mTc-protein conjugates, Bioconj. Chem., 2, 333, 1991.
141. Babich, J. W., Solomon, H., Pike, M. C., Kroon, D., Graham, W., Abrams, M. J., Tompkins, R. G., Rubin, R. H., and Fischman, A. J., Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection, J. Nucl. Med., 34, 1964, 1993.
142. m-MAG3-HSA as possible blood pool agents, Nucl. Med. Comm., 16, 942, 1995.
143. 99mTc using aminocarboxylates as coligands, Bioconj. Chem., 7, 63, 1996.
144. 99mTc, Bioconjug. Chem., 8, 146, 1997.
145. Kozak, R. W., Raubitschek, A., Mirzadeh, S., Brechbeil, M. W., Junghaus, R., Gansow, O. A., and Waldmann, T. A., Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: Critical factors in determining in vivo survival and organ toxicity, Cancer Res., 49, 2639, 1989.
146. Deshpande, S. V., DeNardo, S. J., Kukis, D. L., Mori, M. K., McCall, M. J., DeNardo, G. L., and Meares, C. F., Yttrium-90-labeled monoclonal antibody for therapy: Labeling by a new macrocyclic bifunctional chelating agent, J. Nucl. Med., 31, 473, 1990.
147. Adams, G. P., DeNardo, S. J., Deshpande, S. V., DeNardo, G. L., Kukis, D. L., McCall, M. J., and Meares, C. F., Dual isotope pharmacokinetics of an anti-lymphoma antibody (LYM-1) with a new bifunctional chelating agent, J. Nuc. Med., 31, 823, 1990.
148. Meares, C. F., Mori, M. K., Diril, H., Kukis, D. L., McCall, M. J., Deshpande, S. V., DeNardo, S. J., Snook, D., and Epenetos, A. A., Macrocyclic chelates of radiometals for diagnosis and therapy, Br. J. Can., 62 (Suppl. X), 21, 1990.
149. 90Y from cyclic and acyclic ligand-antibody conjugates, Nucl. Med. Biol., 18, 469, 1991.
150. Li, M. and Meares, C. F., Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding
151. DeNardo, S. J., Zhong, G.-R., Salako, Q., Li, M., DeNardo, G. L., and Meares, C. F., Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice, J. Nucl. Med., 36, 829, 1995.
152. 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: Comparison of stable and chemically labile linker systems, Bioconj. Chem., 9, 87, 1998.
153. DeNardo, S. J., Kukis, D. L., Miers, L. A., Winthrop, M. D., Kroger, L. A., Salako, Q., Shen, S., Lamborn, K. R., Gumerlock, P. H., Meares, C. F., and DeNardo, G. L., Yttrium-90-DOTA-chimeric L6 radioimmunoconjugate: Efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts, J. Nucl. Med., 39, 842, 1998.
154. 4 chelate in vitro and in vivo using tumor-bearing nude mice, Nucl. Med. Biol., 19, 205, 1992.
155. Breitz, H. B., Weiden, P. L, Vanderheyden, J.-L., Appelbaum, J. W., Bjorn, M. J., Fer, M. F., Wolf, S. B., Ratliff, B. A., Seiler, C. A., Foisie, D. C., Fisher, D. R., Schroff, R. W., Fritzberg, A. R., and Abrams, P. G., Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials, J. Nucl. Med., 33, 1099, 1992.
156. 186Re using the MAG3 chelate for radioimmunotherapy of cancer: A technical protocol, J. Nucl. Med., 34, 1953, 1993.
157. 186Re labeling of monoclonal antibodies, Cancer, 73, 769, 1994.
158. van Gog, F. B., Visser, G. W. M., Klok, R., van der Schors, R., Snow, G. B., and van Dongen, G. A. M. S., Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: Relationship between the number of chelated groups and biodistribution characteristics, J. Nucl. Med., 37, 352, 1996.